


Docket No.: TEX4542P0403US

IN THE CLAIMS:Please amend the claims as follows:

1. (Currently Amended) A compound of the structure



wherein Y, at each occurrence, is independently selected from the group consisting of C(O), N, CR¹, C(R²)(R³), NR⁵ and CH;

q is an integer of from 3 to 6;

A is NR⁶;

E is NR⁷;

J is O;

T is (CH₂)_b wherein b is an integer of from 0 to 2;

M is selected from the group consisting of C(R⁹)(R¹⁰) and

(CH₂)_u wherein u is an integer of from 0 to 1;

L is (CH₂)_n wherein n is an integer of 0 or 1;

X is selected from the group consisting of CO₂B, and tetrazolyl;

W is selected from the group consisting of C and CR¹⁵;

B is H or alkyl;

R¹ at each occurrence is independently selected from the group consisting of

hydrogen, halogen, alkyl, alkoxy, -CF₃, -NH₂, -OH, -NHC(O)N(C₁-C₃

alkyl)C(O)NH(C₁-C₃ alkyl), -NHSO₂(C₁-C₃ alkyl), alkylamino, di(C₁-C₃

alkyl)amino, cycloalkyl, aryl, arylamino, heterocyclic 1,4-oxazinan-4-yl, 4-

methyltetrahydro-1(2H)-pyrazinyl, 1-azetanyl and sulfonamido;

Docket No.: TEX4542P0403US

R^2 and R^3 are hydrogen;

R^4 is selected from the group consisting of

hydrogen, alkyl, aryl, biaryl, ~~heterocycly4~~, alkylaryl, and aralkyl,
~~heterocyclyalkyl and alkylheterocycly4~~;

R^5 at each occurrence is independently selected from the group consisting of

alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, ~~heterocyclyalkyl, heterocycly4~~ and aryloxyalkyl;

R^6 and R^7 are independently hydrogen or alkyl;

R^9 and R^{10} are independently selected from the group consisting of hydrogen, alkyl and halogen; and

R^{15} is hydrogen;

wherein B , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^9 , R^{10} and R^{15} are unsubstituted or substituted with at least one electron donating or electron withdrawing group;

~~and wherein when A is NR^6 and at least one Y is CR^4 , R^4 and R^6 taken together may form a ring;~~

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound of claim 1 wherein

A is NR^6 ;

E is NR^7 ;

J is O ;

M is $C(R^9)(R^{10})$;

q is 4 or 5;

T is $(CH_2)_b$ wherein b is 0;

L is $(CH_2)_n$ wherein n is 0;

X is CO_2B ;

W is C or CR^{15} ;


R^4 is selected from the group consisting of aryl, alkylaryl, aralkyl, and ~~heterocycly4~~;

Docket No.: TEX4542P0403US

~~alkylheterocyclyl and heterocyclylalkyl; and~~
 R^6, R^7, R^9, R^{10} and R^{15} are independently selected from the group consisting of hydrogen and lower alkyl.

3. (Original) A compound of claim 1 which is a derivative thereof selected from the group consisting of esters, carbamates, aminals, amides, optical isomers and pro-drugs.

4. (Currently Amended) A compound of the structure



wherein Y, at each occurrence, is independently selected from the group consisting of $C(O)$, N , CR^1 , $C(R^2)(R^3)$, NR^5 and CH ;

q is an integer of from 3 to 6;

T is $(CH_2)_b$ wherein b is an integer of 0 to 2;

L is $(CH_2)_n$ wherein n is an integer of 0 or 1;

W is selected from the group consisting of C and CR^{15} ;

B is H or alkyl;

R^1 at each occurrence is independently selected from the group consisting of

hydrogen, halogen, alkyl, alkoxy, $-CF_3$, $-NH_2$, $-OH$, $-NHC(O)N(C_1-C_3$ alkyl) $C(O)NH(C_1-C_3$ alkyl), $-NHSO_2(C_1-C_3$ alkyl), alkylamino, di(C_1-C_3 alkyl)amino, cycloalkyl, aryl, arylamino, heterocyclyl 1,4-oxazinan-4-yl, 4-methyltetrahydro-1(2H)-pyrazinyl, 1-azetanyl and sulfonamido;

R^2 and R^3 are hydrogen;

R^4 is selected from the group consisting of

Docket No.: TEX4542P0403US

hydrogen, alkyl, aryl, biaryl, ~~heterocyclyl, alkylaryl, and aralkyl,~~ heterocyclylalkyl and alkylheterocyclyl;

R^5 at each occurrence is independently selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, ~~heterocyclylalkyl, heterocyclyl~~ and aryloxyalkyl;

R^6 and R^7 are independently hydrogen or alkyl; and

R^9 and R^{10} are independently selected from the group consisting of hydrogen, alkyl and halogen; and

R^{15} is hydrogen;

wherein B, R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^9 , R^{10} and R^{15} are unsubstituted or substituted with at least one electron donating or electron withdrawing group;

~~and wherein when at least one Y is CR₁R₂ and R₁ and R₂ taken together may form a ring;~~

or a pharmaceutically acceptable salt thereof.

5. (Original) A compound of claim 4 wherein

q is 4 or 5;

W is C or CR¹⁵;

T is (CH₂)_b wherein b is 0;


L is (CH₂)_n wherein n is 0;

R^4 is selected from the group consisting of aryl, alkylaryl, and aralkyl, heterocyclyl, alkylheterocyclyl and heterocyclylalkyl; and R^6 , R^7 , R^9 , R^{10} and R^{15} are independently selected from the group consisting of hydrogen and lower alkyl.

6. (Original) A compound of claim 4 which is a derivative thereof selected from the group consisting of esters, carbamates, aminals, amides, optical isomers and pro-drugs.

7. (Currently Amended) A compound of the structure

Docket No.: TEX4542P0403US



wherein Y, at each occurrence, is independently selected from the group

consisting of C(O), N, CR¹, C(R²)(R³) and CH;

q is an integer of from 2 to 4;

T is (CH₂)_b wherein b is an integer of 0 to 2;

L is (CH₂)_n wherein n is an integer of 0 or 1;

B is H or alkyl;

R¹ at each occurrence is independently selected from the group consisting of

hydrogen, halogen, alkyl, alkoxy, -CF₃, -NH₂, -OH, -NHC(O)N(C₁-C₃

alkyl)C(O)NH(C₁-C₃ alkyl), -NHSO₂(C₁-C₃ alkyl), alkylamino, di(C₁-C₃

alkyl)amino, cycloalkyl, aryl, arylamino, ~~heterocyclic~~ 1,4-oxazinan-4-yl, 4-

methyltetrahydro-1(2H)-pyrazinyl, 1-azetanyl and sulfonamido;

R² and R³ are hydrogen;

R⁴ is selected from the group consisting of

Docket No.: TEX4542P0403US

hydrogen, alkyl, aryl, biaryl, ~~heterocyclyl~~, alkylaryl, and aralkyl;

~~heterocyclylalkyl and alkylheterocyclyl;~~

R^6 R^7 are independently hydrogen or alkyl;

R^9 and R^{10} are independently selected from the group of

hydrogen, alkyl and halogen; and

R^{18} is selected from the group consisting of

hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, ~~alkylheterocyclyl~~,

~~heterocyclylalkyl, heterocyclyl and aryloxyalkyl;~~

wherein B, R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^9 , R^{10} , R^{11} and R^{18} are unsubstituted or substituted with at least one electron donating or electron withdrawing group;

~~and wherein when at least one Y is CR^1 , R^2 and R^3 taken~~

~~together may form a ring;~~

or a pharmaceutically acceptable salt thereof.

8. (Original) A compound of claim 7 wherein R^{18} is selected from the group consisting

of hydrogen, alkyl, aryl, aralkyl, and cycloalkyl, ~~alkylheterocyclyl~~,

~~heterocyclylalkyl and heterocyclyl;~~

T is $(CH_2)_b$ wherein b is 0;

L is $(CH_2)_n$ wherein n is 0;


Y is selected from the group consisting of CR^1 and $C(R^2)(R^3)$ and

q is 2 or 3.


9. (Original) A compound of claim 7 which is a derivative thereof selected from the group consisting of esters, carbamates, aminals, amides, optical isomers and pro-drugs.

Docket No.: TEX4542P0403US

10. (Currently Amended) A compound of claim 7 wherein



is selected from the group consisting of



wherein R¹⁸ is selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclylalkyl, heterocyclyl and aryloxyalkyl;

R¹⁹ at each occurrence is independently selected from the group consisting of alkyl, heterocyclyl and aryl;

Docket No.: TEX4542P0403US

R^{20} at each occurrence is independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, $-CF_3$, $-NH_2$, $-OH$, $-NHC(O)N(C_1-C_3$ alkyl) $C(O)NH(C_1-C_3$ alkyl), $-NHSO_2(C_1-C_3$ alkyl), alkylamino, di(C_1-C_3 alkyl)amino, cycloalkyl, aryl, arylamino, 1,4-oxazinan-4-yl, 4-methyltetrahydro-1(2H)-pyrazinyl, 1-azetanyl heterocyclyl and sulfonamido;

R^{21} is hydrogen;

R^{22} is hydroxy;

R^{28} at each occurrence is independently selected from the group consisting of alkyl and hydroxy;

c is an integer of zero to two;

d is an integer of zero to three;

e is an integer of zero to four; and

i is an integer of zero to two.

11. (Original) The compound of claim 7 wherein R^{18} is aralkyl;


R^4 is aryl;

T is $(CH_2)_b$ where b is zero;

L is $(CH_2)_n$ where n is zero; and,

B , R^6 , R^7 , R^9 and R^{10} are each independently hydrogen.

12. (Currently Amended) A compound of the structure



Docket No.: TEX4542P0403US

wherein T is $(\text{CH}_2)_b$, wherein b is an integer of from 0 to 2;

L is $(\text{CH}_2)_n$ wherein n is an integer of 0 or 1;

g is an integer of from 0 to 7;

B is H or alkyl;

R^4 is selected from the group consisting of

hydrogen, alkyl, aryl, biaryl, ~~heterocyclyl~~, alkylaryl, and aralkyl,
~~heterocyclylalkyl~~ and ~~alkylheterocyclyl~~;

R^6 and R^7 are independently hydrogen or alkyl;

R^9 and R^{10} are independently selected from the group consisting of

hydrogen, alkyl and halogen;

R^{18} is selected from the group consisting of

alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, ~~heterocyclylalkyl~~, ~~heterocyclyl~~
and aryloxyalkyl; and

R^{23} at each occurrence is independently selected from the group consisting of


hydrogen, halogen, alkyl, alkoxy, $-\text{CF}_3$, $-\text{NH}_2$, $-\text{OH}$, $-\text{NHC(O)N(C}_1\text{-C}_3$
 $\text{alkyl)C(O)NH(C}_1\text{-C}_3\text{ alkyl)}$, $-\text{NHSO}_2(\text{C}_1\text{-C}_3\text{ alkyl)}$, alkylamino, di($\text{C}_1\text{-C}_3$
alkyl)amino, cycloalkyl, aryl, arylamino, 1,4-oxazinan -4-yl, 4-methyltetrahydro -
1(2H)- pyrazinyl, 1-azetanyl ~~heterocyclyl~~ and sulfonamido;

Docket No.: TEX4542P0403US

wherein B, R⁴, R⁶, R⁷, R⁹, R¹⁰, R¹⁸ and R²³ are unsubstituted or substituted with at least one electron donating or electron withdrawing group; or a pharmaceutically acceptable salt thereof.

13. (Original) A compound of claim 12 which is a derivative thereof selected from the group consisting of esters, carbamates, aminals, amides, optical isomers and pro-drugs.

14. (Currently Amended) A compound of the structure



wherein h is an integer of zero to five;

B, R⁶, R⁷, R⁹, R¹⁰ are independently selected from the group consisting of hydrogen and alkyl;

R¹⁸ is selected from the group consisting of

alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclylalkyl, heterocyclyl and aryloxyalkyl;

R²⁴ is selected from the group consisting of hydrogen, alkyl and aryl;

Docket No.: TEX4542P0403US

R^{25} is selected from the group consisting of hydrogen, halogen, alkyl and cycloalkyl;

R^{26} is selected from the group consisting of hydrogen, alkyl and aralkyl; and

R^{27} at each occurrence is independently selected from the group consisting of

halogen, hydroxyl, alkyl, alkoxy, thioalkoxy, $-CF_3$, alkylamino, alkenylamino,

di(C_1 - C_3 alkyl)amino, haloalkyl, alkoxyalkoxy, cycloalkyl, aryl, sulfonyl and -

$SO_2-(C_1-C_3$ alkyl);

wherein B , R^6 , R^7 , R^9 , R^{10} , R^{18} , R^{24} , R^{25} , R^{26} and R^{27} are unsubstituted or substituted

with at least one electron donating or electron withdrawing group;

wherein R^{24} and R^{25} taken together may form a ring;


or a pharmaceutically acceptable salt thereof.

15. (Previously Amended) The compound of claim 14 wherein B , R^6 , R^7 , R^9 , R^{10} , R^{24} , R^{25} and R^{26} are each independently hydrogen or alkyl and R^{18} is substituted or unsubstituted aralkyl.

16. (Original) A compound of claim 14 which is a derivative thereof selected from the group consisting of esters, carbamates, aminals, amides, optical isomers and pro-drugs.

17. (Currently Amended) A compound of the structure

Docket No.: TEX4542P0403US



wherein Z, at each occurrence, is independently selected from the group consisting

of CR³⁰, C(R³¹)(R³²), CH, O and S;

z is an integer of from 3 to 5;

k is 1;

T is (CH₂)_b wherein b is an integer of from 0 to 1;

L is (CH₂)_n wherein n is an integer of 0 or 1;

B is selected from the group consisting of

hydrogen and alkyl;

R⁴ is selected from the group consisting of

hydrogen, aryl, alkyl, aralkyl, heterocyclic and biaryl;

R⁶, R⁷, R⁹, R¹⁰, R³⁰, R³¹ and R³² are hydrogen;

R¹⁸ is aralkyl; and

R²⁹ is hydroxyl;

wherein B, R⁴, R⁶, R⁷, R⁹, R¹⁰, R¹⁸, R²⁹, R³⁰, R³¹ and R³² are

Docket No.: TEX4542P0403US

unsubstituted or substituted with at least one electron donating or electron withdrawing group;
or a pharmaceutically acceptable salt thereof.

18. (Original) A compound of claim 17 which is a derivative thereof selected from the group consisting of esters, carbamates, aminals, amides, optical isomers and prodrugs.

19. (Original) The compound of claim 17 wherein z is three or four.

20. (Withdrawn)

21. (Withdrawn)

22. (Withdrawn)

23. (Withdrawn)

24. (Withdrawn)

25. (Original) A compound selected from the group consisting of (3S)-3-[(2-methyl-4-(2-methylpropyl)-6-oxo-1-(phenylmethyl)-1,6-dihydro-5-pyrimidinyl]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid, (3S)-3-(1,3-benzodioxol-5-yl)-3-[(2-oxo-1-(phenylmethyl)-4-propyl-1,2-dihydro-3-pyridinyl]amino}carbonyl)amino]propanoic acid, (3S)-3-{[(1-[(2-chlorophenyl)methyl]-4-ethyl-2-oxo-1,2-dihydro-3-pyridinyl]amino}carbonyl]amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{[(1-[(2-chlorophenyl)methyl]-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl]amino}carbonyl]amino}-3-(4-methylphenyl)propanoic acid,

Docket No.: TEX4542P0403US

(3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{6-methyl-2-oxo-1-(phenylmethyl)-4-[(phenylmethyl)oxy]-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-2,4-dimethyl-6-oxo-1,6-dihydro-5-yrimidinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{4-amino-1-[(2-chlorophenyl)methyl]-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-[4-(methyloxy)phenyl]propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(3,4-dimethylphenyl)propanoic acid, (3S)-3-{{{{4-amino-1-[(2-chlorophenyl)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-(1,4-oxazinan-4-yl)-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-2-oxo-4-(propylamino)-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-bromophenyl)methyl]-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-[3-methyl-4-(methyloxy)phenyl]propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-2-oxo-4-phenyl-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-[(2-[(2-methoxyethyl)oxy]ethyl)oxy]-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-hydroxy-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-[(1,1-dimethylethyl)amino]-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-

Docket No.: TEX4542P0403US

phenylpropanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-[4-methyltetrahydro-1(2H)-pyrazinyl]-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-[4-(methyloxy)phenyl]propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(3,5-dimethylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(3-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-[3-(methyloxy)phenyl]propanoic acid, (3S)-3-[3,5-bis(methyloxy)phenyl]-3-{{{{1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-quinoliny}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-[3-(trifluoromethyl)phenyl]propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-[(ethyl[(ethylamino)carbonyl]amino)carbonyl]amino}carbonyl}amino}-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl]amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{4-(1-azetanyl)-1-[(2-chlorophenyl)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-4-[(2-[(2-(methyloxy)ethyl]oxy)ethyl]oxy}ethyl]oxy}-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl]amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chloro-6-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-{{{{1-[(2-chlorophenyl)methyl]-5-methyl-2-oxo-1,2-dihydro-3-pyridinyl}amino}carbonyl}amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-(1,3-benzodioxol-5-yl)-3-(((2-oxo-1-((4-(trifluoromethyl)phenyl)methyl)-1,2-dihydro-3-pyridinyl)amino)carbonyl)amino)propanoic acid, (3S)-3-(((1-((2-chlorophenyl)methyl)-2-oxo-1,2-dihydro-3-pyridinyl)amino)carbonyl)amino)-3-(4-methylphenyl)propanoic acid, (3S)-3-(((1-((2-fluorophenyl)methyl)-2-oxo-1,2-dihydro-3-pyridinyl)amino)carbonyl)amino)-3-(4-

Docket No.: TEX4542P0403US

methylphenyl)propanoic acid, (3S)-3-(((1-((2-bromophenyl)methyl)-2-oxo-1,2-dihydro-3-pyridinyl)amino)carbonyl)amino)-3-(4-methylphenyl)propanoic acid, (3S)-3-(((1-((2,4-dichlorophenyl)methyl)-2-oxo-1,2-dihydro-3-pyridinyl)amino)carbonyl)amino)-3-(4-methylphenyl)propanoic acid, (3S)-3-(((1-((2-chloro-6-fluorophenyl)methyl)-2-oxo-1,2-dihydro-3-pyridinyl)amino)carbonyl)amino)-3-(4-methylphenyl)propanoic acid, (3S)-3-(((1-((2-chlorophenyl)methyl)-4-hydroxy-2-oxo-1,2-dihydro-3-pyridinyl)amino)carbonyl)amino)-3-(4-trifluoromethyl)oxy)phenyl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-methoxybenzyl)-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid, 4-{{[3-[({(1S)-2-carboxy-1-(4-methylphenyl)ethyl}amino}carbonyl)amino]-1-(2-chlorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]amino}benzoic acid, (3S)-3-[{({1-(2-chlorobenzyl)-4-[2,2-dimethylpropanoyl]amino}-2-oxo-1,2-dihydropyridin-3-yl)amino}carbonyl]amino}-3-(4-methylphenyl)propanoic acid, (3S)-3-[{[4-{{(tert-butylamino)carbonyl}amino}-1-(2-chlorobenzyl)-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl]amino]-3-(4-methylphenyl)propanoic acid, (3S)-3-[{[1-(2-cyanobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl]amino]-3-(4-methylphenyl)propanoic acid, (3S)-3-[{[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl]amino]-3-(2,3-dihydro-1,4-benzodioxin-6-yl)propanoic acid, (3S)-3-[{[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl]amino]-3-(7-methoxy-1,3-benzodioxol-5-yl)propanoic acid, (3S)-3-[{[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl]amino]-3-(3-ethoxy-4-methoxyphenyl)propanoic acid, (3S)-3-[{[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl]amino]-3-(3,4-dimethoxyphenyl)propanoic acid, (3S)-3-[{[1-(4-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl]amino]-3-(4-methylphenyl)propanoic acid, (3S)-3-[{[1-(2-chloro-6-methoxybenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl]amino]-3-(4-methylphenyl)propanoic acid, (3S)-3-[{[1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl]amino]-3-(4-methylphenyl)propanoic acid, (3S)-3-[{[1-(2,6-difluorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl]amino]-3-(4-methylphenyl)propanoic acid, (3S)-3-[{[1-(2-chloro-6-methoxybenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl]amino]-3-(3,5-dimethoxyphenyl)propanoic acid, (3S)-3-

Docket No.: TEX4542P0403US

Docket No.: TEX4542P0403US

chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(3,4-dipropoxyphenyl)propanoic acid, (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-[3-(difluoromethoxy)phenyl]propanoic acid, (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(3,4-diethoxyphenyl)propanoic acid, (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(3,4-diethoxyphenyl)propanoic acid, (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(3,4-diethoxyphenyl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-methylbenzyl)-4-hydroxy-5,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(3,4-diethoxyphenyl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-cyanobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(4-methylphenyl)propanoic acid, 3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(2-naphthyl)propanoic acid, (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-5,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(3,4-diethoxyphenyl)propanoic acid (3S)-3-[({[1-(2-chloro-6-methoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(3,4-diethoxyphenyl)propanoic acid, (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(3-isopropoxyphenyl)propanoic acid, (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(4-methoxyphenyl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-methylbenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl]amino} carbonyl)amino]-3-(3-ethoxyphenyl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(3-ethoxyphenyl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(3-isopropoxyphenyl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl]amino} carbonyl)amino]-3-(3-ethoxyphenyl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(1-methyl-1H-indol-5-yl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino} carbonyl)amino]-3-(2,3-dihydro-1-benzofuran-5-yl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-4-

Docket No.: TEX4542P0403US

hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl]amino}carbonyl)amino]-3-(3,5-diethoxyphenyl)propanoic acid, (3S)-3-[({[5-chloro-1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-(3-ethoxyphenyl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-(3-isopropoxyphephenyl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl]amino}carbonyl)amino]-3-(3-propoxyphephenyl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl]amino}carbonyl)amino]-3-phenylpropanoic acid, (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl]amino}carbonyl)amino]-3-(1,3-diethyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-[3-(trifluoromethoxy)phenyl]propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-(3-isopropoxyphephenyl)propanoic acid, (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl]amino}carbonyl)amino]-3-(1-methyl-1H-indol-5-yl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-5-cyclopropyl-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-(3-isopropoxyphephenyl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-5-cyclopropyl-4-hydroxy-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid, (3S)-3-[({[1-(2-chloro-5-methoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-(3-isopropoxyphephenyl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-(1-methyl-1H-indol-6-yl)propanoic acid, (3S)-3-[({[1-(2-chloro-6-ethoxybenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl]amino}carbonyl)amino]-3-[3-(cyclopropyloxy)phenyl]propanoic acid, (3S)-3-[({[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl]amino}carbonyl)amino]-3-[3-(cyclopropylmethoxy)phenyl]propanoic acid, (3S)-3-[({[1-(2-

Docket No.: TEX4542P0403US

chloro-6-ethoxybenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl]amino}carbonyl)amino]-3-[3-(cyclopropylmethoxy)phenyl]propanoic acid, (3S)-3-{{[1-(2-chlorobenzyl)-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl]amino}carbonyl)amino]-3-(3,5-dimethylphenyl)propanoic acid, (3S)-3-{{[1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl}amino}carbonyl]amino}-3-{3-[(difluoromethyl)oxy]phenyl}propanoic acid, (3S)-3-{{[1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl}amino}carbonyl]amino}-3-{3-[(1,1,2,2-tetrafluoroethyl)oxy]phenyl}propanoic acid, (3S)-3-{{[1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl}amino}carbonyl]amino}-3-(1-ethyl-1H-indol-5-yl)propanoic acid and (3S)-3-{{[1-[(2-chlorophenyl)methyl]-4-hydroxy-2-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[b]pyridin-3-yl}amino}carbonyl]amino}-3-[3-(diethylamino)phenyl]propanoic acid and pharmaceutical acceptable salts thereof.

26. (Original) (3S)-3-{{[1-(2-chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3-yl]amino}carbonyl)amino]-3-(4-methylphenyl)propanoic acid and pharmaceutical acceptable salts thereof.

27. (Withdrawn)

28. (Withdrawn)

29. (Withdrawn)

30. (Original) A pharmaceutical composition comprising:
a compound of claim 1
in a pharmaceutically acceptable carrier.

31. (Original) A method for selectively inhibiting $\alpha_4\beta_1$ integrin binding in a mammal comprising administering to said mammal a therapeutic amount of a compound of claim 1.